title: Suivi thérapeutique pharmacologique de la prégabaline.
abstract: Pregabaline, a second generation antiepileptic, is marketed in France since 2005. It is also indicated in the treatment of painful neuropathy and in generalized anxious disorder. Its pharmacokinetic profile: low metabolism and no binding to plasma proteins, is not in favour of the necessity of a TDM. But other studies would be necessary to concluded more definitively. Pregabalin however, required a dosage adjustment in case of renal insufficiency. The values of the plasma concentrations found after various doses are in agreement in the different studies, without that we can define a therapeutic range. For this molecule, the level of proof of the interest of TDM was estimated in: remaining to estimate.
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France. Electronic address: daniele.bentue-ferrer@univ-rennes1.fr.
authors.forename: Danièle
authors.initials: D
authors.lastname: Bentué-Ferrer
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tribut
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Marie-Clémence
authors.initials: MC
authors.lastname: Verdier
keywords: Pregabalin; Prégabaline; monitoring; pharmacologique; suivi thérapeutique; therapeutic drug